Literature DB >> 16622476

Adoptive immunotherapy for cancer: building on success.

Luca Gattinoni1, Daniel J Powell, Steven A Rosenberg, Nicholas P Restifo.   

Abstract

Adoptive cell transfer after host preconditioning by lymphodepletion represents an important advance in cancer immunotherapy. Here, we describe how a lymphopaenic environment enables tumour-reactive T cells to destroy large burdens of metastatic tumour and how the state of differentiation of the adoptively transferred T cells can affect the outcome of treatment. We also discuss how the translation of these new findings might further improve the efficacy of adoptive cell transfer through the use of vaccines, haematopoietic-stem-cell transplantation, modified preconditioning regimens, and alternative methods for the generation and selection of the T cells to be transferred.

Entities:  

Mesh:

Year:  2006        PMID: 16622476      PMCID: PMC1473162          DOI: 10.1038/nri1842

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  140 in total

Review 1.  CD28-mediated co-stimulation: a quantitative support for TCR signalling.

Authors:  Oreste Acuto; Frédérique Michel
Journal:  Nat Rev Immunol       Date:  2003-12       Impact factor: 53.106

2.  MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation.

Authors:  Naoyuki Fujita; David L Jaye; Cissy Geigerman; Adil Akyildiz; Myesha R Mooney; Jeremy M Boss; Paul A Wade
Journal:  Cell       Date:  2004-10-01       Impact factor: 41.582

Review 3.  Immunodominance and tumor escape.

Authors:  H Schreiber; T H Wu; J Nachman; W M Kast
Journal:  Semin Cancer Biol       Date:  2002-02       Impact factor: 15.707

4.  Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

Authors:  Joseph T Opferman; Anthony Letai; Caroline Beard; Mia D Sorcinelli; Christy C Ong; Stanley J Korsmeyer
Journal:  Nature       Date:  2003-12-11       Impact factor: 49.962

5.  Selective stimulation of T cell subsets with antibody-cytokine immune complexes.

Authors:  Onur Boyman; Marek Kovar; Mark P Rubinstein; Charles D Surh; Jonathan Sprent
Journal:  Science       Date:  2006-02-16       Impact factor: 47.728

6.  Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells.

Authors:  Adam P Kohm; Jeffrey S McMahon; Joseph R Podojil; Wendy Smith Begolka; Mathew DeGutes; Deborah J Kasprowicz; Steven F Ziegler; Stephen D Miller
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

Review 7.  Regulatory T cells and Toll-like receptors in tumor immunity.

Authors:  Rong-Fu Wang; Guangyong Peng; Helen Y Wang
Journal:  Semin Immunol       Date:  2006-02-15       Impact factor: 11.130

8.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors:  Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307

9.  Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells.

Authors:  B K Cho; V P Rao; Q Ge; H N Eisen; J Chen
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

10.  Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans.

Authors:  Valérie Dutoit; Verena Rubio-Godoy; Mikäel J Pittet; Alfred Zippelius; Pierre-Yves Dietrich; Frédérique Anne Legal; Philippe Guillaume; Pedro Romero; Jean-Charles Cerottini; Richard A Houghten; Clemencia Pinilla; Danila Valmori
Journal:  J Exp Med       Date:  2002-07-15       Impact factor: 14.307

View more
  334 in total

Review 1.  Tissue-specific homing of immune cells in malignant skin tumors.

Authors:  Hajnalka Jókai; Márta Marschalkó; Judit Csomor; József Szakonyi; Orsolya Kontár; Gábor Barna; Sarolta Kárpáti; Péter Holló
Journal:  Pathol Oncol Res       Date:  2012-04-24       Impact factor: 3.201

Review 2.  Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy.

Authors:  Luca Gattinoni; Yun Ji; Nicholas P Restifo
Journal:  Clin Cancer Res       Date:  2010-08-05       Impact factor: 12.531

Review 3.  The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders.

Authors:  Anna Merlo; Riccardo Turrini; Riccardo Dolcetti; Debora Martorelli; Elena Muraro; Patrizia Comoli; Antonio Rosato
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

4.  Pharmacologic induction of CD8+ T cell memory: better living through chemistry.

Authors:  Luca Gattinoni; Christopher A Klebanoff; Nicholas P Restifo
Journal:  Sci Transl Med       Date:  2009-12-16       Impact factor: 17.956

5.  Predicting cytotoxic T-cell age from multivariate analysis of static and dynamic biomarkers.

Authors:  Catherine A Rivet; Abby S Hill; Hang Lu; Melissa L Kemp
Journal:  Mol Cell Proteomics       Date:  2010-12-30       Impact factor: 5.911

Review 6.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 7.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Authors:  Yunlu Dai; Can Xu; Xiaolian Sun; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2017-05-18       Impact factor: 54.564

8.  Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64.

Authors:  Parijat Bhatnagar; Zheng Li; Yoonsu Choi; Jianfeng Guo; Feng Li; Daniel Y Lee; Matthew Figliola; Helen Huls; Dean A Lee; Tomasz Zal; King C Li; Laurence J N Cooper
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

9.  In vitro induction of T cells that are resistant to A2 adenosine receptor-mediated immunosuppression.

Authors:  Akio Ohta; J Kjaergaard; S Sharma; M Mohsin; N Goel; M Madasu; E Fradkov; Akiko Ohta; M Sitkovsky
Journal:  Br J Pharmacol       Date:  2008-12-09       Impact factor: 8.739

Review 10.  Immunotherapy and immunoescape in colorectal cancer.

Authors:  Guillermo Mazzolini; Oihana Murillo; Catalina Atorrasagasti; Juan Dubrot; Iñigo Tirapu; Miguel Rizzo; Ainhoa Arina; Carlos Alfaro; Arantza Azpilicueta; Carmen Berasain; José L Perez-Gracia; Alvaro Gonzalez; Ignacio Melero
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.